Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
28888 | 161 | 35.0 | 85% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
157 | 21931 | BENIGN PROSTATIC HYPERPLASIA//PROSTATE CANCER//PROSTATE |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | PEROPERATIVE BLEEDING | Author keyword | 2 | 67% | 1% | 2 |
2 | PRIMARY PROSTATE CULTURE | Author keyword | 1 | 100% | 1% | 2 |
3 | BLOOD VESSEL MORPHOLOGY | Author keyword | 1 | 50% | 1% | 1 |
4 | DUCTAL MORPHOLOGY | Author keyword | 1 | 50% | 1% | 1 |
5 | RECEPTORS VASOACTIVE INTESTINAL PEPTIDE | Author keyword | 1 | 50% | 1% | 1 |
6 | REGULATION OF PROSTATE GROWTH | Author keyword | 1 | 50% | 1% | 1 |
7 | SURG PERIOOPERAT SCI | Address | 1 | 50% | 1% | 1 |
8 | VASC HEMATOL | Address | 1 | 50% | 1% | 1 |
9 | VESSEL COUNTS | Author keyword | 1 | 50% | 1% | 1 |
10 | CLIN BIOCHEM AKH | Address | 0 | 33% | 1% | 1 |
Web of Science journal categories |
Author Key Words |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | HEMATURIA SECONDARY | 15 | 68% | 8% | 13 |
2 | R3327 PAP ADENOCARCINOMA | 3 | 60% | 2% | 3 |
3 | FACTOR VEGF EXPRESSION | 2 | 13% | 9% | 15 |
4 | BPH PATIENTS | 1 | 50% | 1% | 1 |
5 | CASTRATION TREATMENT | 1 | 50% | 1% | 1 |
6 | FINASTERIDE TREATMENT | 1 | 29% | 1% | 2 |
7 | DUNNING R3327 | 0 | 33% | 1% | 1 |
8 | EXERCISE RELATED HEMATURIA | 0 | 33% | 1% | 1 |
9 | CASTRATION THERAPY | 0 | 18% | 1% | 2 |
10 | MICROVESSEL DENSITY ANALYSIS | 0 | 17% | 1% | 2 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Role of 5 alpha-reductase inhibitors in benign prostatic diseases | 2012 | 3 | 71 | 31% |
Persistent prostatic hematuria | 2008 | 2 | 28 | 36% |
Hypoxia drives prostate tumour progression and impairs the effectiveness of therapy, but can also promote cell death and serve as a therapeutic target | 2009 | 6 | 81 | 21% |
Angiogenesis and prostate cancer tumor growth | 2004 | 66 | 174 | 7% |
Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer | 2001 | 40 | 168 | 11% |
Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade | 2005 | 11 | 68 | 13% |
Role of androgen and vitamin D receptors in endothelial cells from benign and malignant human prostate | 2013 | 2 | 95 | 13% |
Role of angiogenesis in the progression and treatment of prostate cancer | 2001 | 21 | 107 | 7% |
Targeting angiogenic pathways involving tumor-stromal interaction to treat advanced human prostate cancer | 1998 | 13 | 50 | 12% |
Angiogenesis in prostate cancer: Biology and therapeutic opportunities | 2001 | 24 | 158 | 6% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | SURG PERIOOPERAT SCI | 1 | 50% | 0.6% | 1 |
2 | VASC HEMATOL | 1 | 50% | 0.6% | 1 |
3 | CLIN BIOCHEM AKH | 0 | 33% | 0.6% | 1 |
4 | SURG PEROPERAT SCI UROL ANDROL | 0 | 33% | 0.6% | 1 |
5 | SERV SALUD METROPOLITANO OCCIDENTE | 0 | 25% | 0.6% | 1 |
6 | CLIN CHEM TRANSFUS | 0 | 17% | 0.6% | 1 |
7 | CLIN BG BERGMANNSHEIL | 0 | 100% | 0.6% | 1 |
8 | CYTOKINE CYTOKINE RECEPTOR LINK S | 0 | 100% | 0.6% | 1 |
9 | UNIV CLIN BG BERGMANNSHEIL | 0 | 100% | 0.6% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000274271 | PROSTATE DEVELOPMENT//BIOL SCI VET MED//PROSTATE STEM CELL |
2 | 0.0000273089 | PROSTATIC ARTERY EMBOLIZATION//UNIV ANAT//PROSTATIC ARTERIAL EMBOLIZATION |
3 | 0.0000203513 | PLASMA VEGF//MANCHESTER RENAL GRP//PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR |
4 | 0.0000183745 | LINOMIDE//ROQUINIMEX//LAQUINIMOD |
5 | 0.0000142308 | MICROVESSEL DENSITY//MICROVESSEL COUNT//CHALKLEY |
6 | 0.0000138931 | TRANSURETHRAL RESECTION OF PROSTATE//ELECTROVAPORIZATION//PHOTOSELECTIVE VAPORIZATION OF THE PROSTATE |
7 | 0.0000134618 | UNIT IMMUNOMICROBIO ENVIRONM CARCINOGENESIS//ANTI INTERLEUKIN 6 ANTIBODY//AUTOCRINE AND PARACRINE LOOPS |
8 | 0.0000133978 | HUHS1015//CHRONIC PROSTATIC INFLAMMATION//NAFTOPIDIL |
9 | 0.0000130328 | 5 ALPHA REDUCTASE//FINASTERIDE//BIOL SYST ANIM PROD |
10 | 0.0000117554 | FLT 1//VEGF RECEPTORS//VEGF165B |